Italian API maker rebounds; Patheon takes opioid work;

> Montreal-based Labopharm (TSX: DDS; NASDAQ: DDSS) says that Italy's Gruppo Angelini, which makes the active ingredient for the once-daily depression treatment Trazodone, has resolved all manufacturing process issues raised by the FDA. Announcement

> In an agreement between QRxPharma (ASX: QRX and OTCQX: QRXPY) and Patheon (TSX:PTI), the latter will manufacture clinical supplies of QRxPharma's controlled-release Dual-Opioid formulation for 12-hour pain relief. Release

> The University of Iowa Pharmaceuticals (UIP) has been cleared by the FDA to manufacture and test an aseptically filled, sterile prescription drug for a commercial client. Release

> TruScan 1.3.0, Ahura Scientific's handheld Raman spectrometer for raw material identification and finished product authentication, now boasts availability in the Chinese and German languages. Release

> Schering-Plough says it will expand a Montreal manufacturing facility to the tune of $28 million. Article

And Finally... The Top 15 Women in Pharma. Start slideshow ⇒

Webinar

Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how IPM.ai transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.